GI oncologists discuss the rationale behind the SWOG S1505 study in pancreatic cancer and provide recommendations for managing patients with resectable disease based on the most current data.
Data from the following clinical trials is discussed:
SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mFOLFIRINOX vs gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). (Sohal D, et al. ASCO 2020. Abstract 4504)
ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase 2 trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in pts with borderline resectable pancreatic cancer. (Ghaneh P, et al. ASCO 2020. Abstract 4505)